Skip to content
Markets News
Stocks1 min read

FDA Clears Bayer’s Sunharbo to Reduce Repeat Stroke Risk

Makkler Newsroom
November 10, 2026 · Based on reporting by finanzen.net, Dünya

The once-daily treatment cut ischemic stroke risk by 26% in a trial, while some patient groups had higher bleeding rates.

Key takeaways

  • The FDA approved Sunharbo for some adults after ischemic stroke or a high-risk transient ischemic attack.
  • In a trial of 12 thousand 327 people, ischemic stroke risk was 26% lower with Sunharbo than placebo.

The FDA approved Bayer’s Sunharbo on Nov. 9 to reduce the risk of another ischemic stroke in certain adults. In a Phase 3 trial, the drug was linked to a 26% lower risk than placebo.

The trial included 12 thousand 327 people who had recently experienced a mild or moderate ischemic stroke or a high-risk transient ischemic attack. Serious bleeding rates were generally similar, but were higher among patients over 75 and during the first 90 days of treatment. Diarrhea was the most common side effect.

Sunharbo is taken once daily alongside standard treatment to prevent blood clots. As of Tuesday afternoon, Bayer shares traded at 56.78 euros, up 0.28% since the previous close.

Topics
BAYNSunharbo
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.